Review Article
Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
| | Cabazitaxel | | Mitoxantrone | |
| OS (months) | 15.1 | | 12.7 | | Median followup (months) | 12.8 | HR 0.70 (0.59–0.83) | PFS (months) | 2.8 | | 1.4 | | PSA progression (months) | 6.4 | | 3.1 | | PSA response rate (%) | 39.2 | | 17.8 | | ORR (%) | 14.4 | | 4.4 | |
| | Abiraterone | | Placebo | |
| OS (months) | 14.8 | | 10.9 | | Median followup (months) | 12.8 | HR 0.65 (0.54–0.77) | PFS (months) | 5.6 | | 3.6 | | PSA progression (months) | 10.2 | | 6.6 | | PSA response rate (%) | 29 | | 6 | | ORR (%) | 14 | | 2.8 | |
| | Enzalutamide | | Placebo | |
| OS (months) | 18.4 | | 13.6 | | Median followup (months) | 14.4 | HR 0.63 (0.53–0.75) | PFS (months) | 8.3 | | 2.9 | | PSA progression (months) | 8.3 | | 3 | | PSA response rate (%) | 54 | | 2 | | ORR (%) | 29 | | 4 | |
|
|